Eli Lilly and Company announced today that Derica Rice, executive vice president global services and chief financial officer, will retire at the end of December 2017 after 27 years of service with the company. Rice is also a member of Lilly’s executive committee.
“On behalf of our shareholders, our board, our executive team and the company, I want to thank Derica for his leadership as our CFO over the past eleven years,” said David A. Ricks, Lilly’s chairman, president and chief executive officer. “Derica has been a core part of Lilly’s turnaround, our innovation strategy and our consistent ability to set and then meet targets and commitments. His personal integrity and commitment to our company has been unwavering.”
“Derica helped navigate the YZ period, served as a trusted advisor to three CEOs, left a lasting impact on Lilly talent across the globe and transformed our global services delivery organization,” said Ricks. “The entire Lilly family would like to thank Derica and wish him the very best in his next set of endeavors.”
Rice joined Lilly in 1990, holding numerous roles in finance and operations throughout his career. He was promoted to his current role in May 2006 after serving as Lilly’s vice president and controller. Rice also has served as Lilly’s general manager in the United Kingdom, executive director and chief financial officer of European operations and chief financial officer for the company’s operations in Canada. Rice earned his MBA from Indiana University and a bachelor’s degree in electrical engineering from the General Motors Institute.
“It’s been a true calling to work at Lilly, helping people live longer, healthier lives. I can’t think of a more noble pursuit than that,” said Rice. “It’s been a wonderful ride and I’m grateful for the opportunity.”
Lilly is considering internal and external candidates to succeed Rice.
Source: Eli Lilly and Company
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.
